STOCK TITAN
  1. Home
  2. News
  3. AZN

Astrazeneca plc - AZN STOCK NEWS

Welcome to our dedicated news page for Astrazeneca plc (Ticker: AZN), a resource for investors and traders seeking the latest updates and insights on Astrazeneca plc.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Astrazeneca plc's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Astrazeneca plc's position in the market.

News
Asher Bio Closes $55 Million Series C Financing to Advance Lead Program into Phase 1b Clinical Trials
Rhea-AI Summary
Asher Biotherapeutics closes $55 million Series C financing led by RA Capital Management to advance lead program AB248 into Phase 1b Clinical Trials with support from AstraZeneca and Bristol Myers Squibb.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.68%
Tags
clinical trial
-
News
IMFINZI® (durvalumab) plus chemotherapy doubled overall survival rate at three years for patients with advanced biliary tract cancer in TOPAZ-1 Phase III trial
Rhea-AI Summary
AstraZeneca's IMFINZI in combination with chemotherapy doubled the overall survival rate at three years for patients with advanced biliary tract cancer in the TOPAZ-1 Phase III trial. The results showed a 26% reduction in the risk of death compared to chemotherapy alone, with a median OS of 12.9 months for the combination therapy. The trial met the primary endpoint of OS in October 2021, showing a 20% reduction in the risk of death. IMFINZI plus chemotherapy continued to be well-tolerated with no new safety signals observed.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.68%
Tags
clinical trial
-
News
FASENRA approved for treatment of children aged 6 to 11 with severe asthma
Rhea-AI Summary
AstraZeneca's FASENRA (benralizumab) receives FDA approval for pediatric patients aged 6 to 11 with severe eosinophilic asthma, expanding treatment options. The approval is based on TATE trial data and prior trials, with a recommended dose of 30 mg for patients 6 years and older.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.97%
Tags
none
News
ENHERTU® Approved in the U.S. as First Tumor Agnostic HER2 Directed Therapy for Previously Treated Patients with Metastatic HER2 Positive Solid Tumors
Rhea-AI Summary
Daiichi Sankyo and AstraZeneca's ENHERTU receives U.S. FDA approval for the treatment of HER2 positive solid tumors after showing clinically meaningful responses. The drug is now approved for five indications, with the latest in metastatic cancers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.37%
Tags
none
-
News
ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US as first tumor-agnostic HER2-directed therapy for previously treated patients with metastatic HER2-positive solid tumors
Rhea-AI Summary
AstraZeneca and Daiichi Sankyo's ENHERTU gains accelerated approval in the US for HER2-positive solid tumors, marking a significant milestone in targeted cancer treatment. The approval is based on positive response rates and duration of response in Phase II trials, leading to inclusion in NCCN Guidelines®.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.37%
Tags
none
-
News
IMFINZI® (durvalumab) significantly improved overall survival and progression-free survival for patients with limited-stage small cell lung cancer in ADRIATIC Phase III trial
Rhea-AI Summary
AstraZeneca's IMFINZI shows survival benefit in Phase III trial for -stage small cell lung cancer, marking a breakthrough in treatment. Positive results in OS and PFS with no new safety signals identified. IMFINZI continues to lead in lung cancer treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.16%
Tags
clinical trial
News
Datopotamab Deruxtecan Biologics License Application Accepted in the U.S. for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer
Rhea-AI Summary
Daiichi Sankyo and AstraZeneca's Biologics License Application for datopotamab deruxtecan has been accepted in the U.S. for the treatment of advanced nonsquamous non-small cell lung cancer and HR positive, HER2 negative breast cancer. The BLA is based on positive results from the TROPION-Breast01 phase 3 trial, with a PDUFA date set for January 29, 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.37%
Tags
none
-
News
VOYDEYA™ approved in the US as add-on therapy to ravulizumab or eculizumab for treatment of extravascular hemolysis in adults with the rare disease PNH
Rhea-AI Summary
VOYDEYA (danicopan) has been approved in the US as an add-on therapy for extravascular hemolysis in adults with paroxysmal nocturnal hemoglobinuria. The approval was based on positive results from the pivotal ALPHA Phase III trial, showing efficacy in addressing EVH. VOYDEYA met primary and secondary endpoints, was well-tolerated, and received Breakthrough Therapy designation and PRIME status.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.74%
Tags
none
-
News
ULTOMIRIS® (ravulizumab-cwvz) approved in the US for the treatment of adults with neuromyelitis optica spectrum disorder (NMOSD)
Rhea-AI Summary
ULTOMIRIS, the first long-acting C5 complement inhibitor, receives US FDA approval for treating AQP4 Ab+ NMOSD, showing a 98.6% relapse risk reduction in the CHAMPION-NMOSD trial. NMOSD is a rare autoimmune disease affecting the CNS, with about 6,000 diagnosed cases in the US. The safety profile of ULTOMIRIS remains consistent with previous studies, with COVID-19, headache, back pain, arthralgia, and urinary tract infection being the most common adverse events.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.6%
Tags
none
News
AstraZeneca to acquire Fusion to accelerate the development of next-generation radioconjugates to treat cancer
Rhea-AI Summary
AstraZeneca acquires Fusion Pharmaceuticals Inc., a clinical-stage company developing radioconjugates for cancer treatment. The acquisition aims to enhance AstraZeneca's oncology portfolio with a focus on prostate cancer treatment. The deal includes a transaction value of approximately $2.4bn, bringing new expertise and capabilities to AstraZeneca.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.02%
Tags
acquisition
Stock AZN logo
Astrazeneca plc

Nasdaq:AZN

AZN Rankings

#39 Ranked by Market Cap
#1673 Ranked by Stock Gains
#1158 Ranked by Dividends

AZN Stock Data

212.97B
1.54B
0.01%
16.8%
0.25%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United Kingdom
Cambridge

About AZN

AstraZeneca plc is a British-Swedish multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, England.